

Natco Pharma Limited Regd. Off.: 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

29<sup>th</sup> September, 2023

Corporate Relationship Department M/s. BSE Limited Dalal Street, Fort Mumbai 400 001. The Manager - Listing M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex Bandra (E) Mumbai 400 051.

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/ Madam,

Sub: Proceedings of the 40<sup>th</sup> Annual General Meeting

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find enclosed herewith the proceedings of the 40<sup>th</sup> Annual General Meeting held on today i.e., 29<sup>th</sup> September 2023.

Please find the weblink for the Video Proceedings of the 40<sup>th</sup> Annual General Meeting: <u>natcopharma.co.in/wp-content/uploads/2023/09/NatcoPharmaAGM-2023.mp4</u>

This is for your information and records.

Thanking you,

Yours Faithfully, For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer

Encl: a.a.



# PROCEEDINGS OF THE 40<sup>TH</sup> ANNUAL GENERAL MEETING OF THE COMPANY HELD ON FRIDAY, THE 29<sup>TH</sup> DAY OF SEPTEMBER, 2023 AT 10.30 A.M. AT THE REGISTERED OFFICE AT NATCO HOUSE, ROAD NO.2, BANJARA HILLS, HYDERABAD 500 034, TELANGANA, INDIA THROUGH VIDEO CONFERENCE

## Directors personally present at the registered office

1. Sri G.S. Murthy	Chairman and Independent Director, Chairman of the Audit Committee, Stakeholders Relationship Committee and Corporate Social Responsibility Committee
2. Sri V.C. Nannapaneni	Managing Director
3. Sri Rajeev Nannapaneni	Director & CEO

### Directors present through video conference from their respective places

4. Dr. T.V. Rao	Independent Director and Chairman of the
	Nomination and Remuneration Committee
5. Sri D.G. Prasad	Independent Director
6. Dr. Leela Digumarti	Independent Director
7. Sri P.S.R.K. Prasad	Director & Executive Vice President
	(Corporate Engineering Services)
8. Dr. D. Linga Rao	Director & President (Technical Affairs)
9. Dr. M.U.R. Naidu	Independent Director
10. Dr. Pavan Ganapati Bhat	Director & Executive Vice President
	(Technical Operations)

### **Company Secretary**

CS Ch. Venkat Ramesh, Company Secretary & Compliance Officer

#### **Others Present**

- (i) Sri S.V.V.N. Appa Rao, Chief Financial Officer.
- (ii) CA Vikash Somani, Partner and CA Ankit Jalan, Associate Director, M/s.B S R & Associates LLP, Statutory Auditors
- (iii) CS B Kiran Kumar, Proprietor, BK & Associates, Practicing Company Secretary, Secretarial Auditors and Scrutinizer for the e-voting process



Natco Pharma Limited Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243 CIN : L24230TG1981PLC003201, www.natcopharma.co.in

A total of 63 members were present during the Annual General Meeting (AGM) through Video Conference.

The Company Secretary of the Company welcomed all the Members and Directors of the Company who were present to the AGM through Video Conference.

Sri G.S. Murthy, Chairman of the Company, occupied the Chair, conducted the proceedings of the meeting and informed that the requisite quorum was present to commence the proceedings:

- Chairman requested Sri Rajeev Nannapaneni, Director & Chief Executive Officer, to read out the Chairman's Speech. Accordingly, the Director & Chief Executive Officer presented the Chairman's Speech to the Members.
- The Chairman informed that with the permission of the Members the notice convening the meeting, Board's Report and other reports were taken as read. The report of Statutory Auditors is unqualified and without any adverse observations or comments in their report and the same was taken as read.
- The Chairman informed the members that the Company has provided remote e-voting facility to the Members from 26<sup>th</sup> September, 2023 (9.00 a.m.) to 28<sup>th</sup> September, 2023 (5.00 p.m.) in order to exercise their right to vote for the items of business of 40<sup>th</sup> AGM. Members who have not availed the remote e-voting facility, for those members e-voting during the AGM has been provided.

ORDINARY BUSINESS:	
1	Adoption of audited Annual Financial Statements for the Financial Year 2022-23
2	To confirm three interim dividends aggregating to Rs.5.50 per share paid on equity shares during the Financial Year 2022-23 as dividend for the FY 2022-23.
3	Re-appointment of Sri Rajeev Nannapaneni (DIN: 00183872) as a Director liable to retire by rotation
4	Re-appointment of Sri P.S.R.K Prasad (DIN: 07011140) as a Director liable to retire
	by rotation
SPECIAL BUSINESS:	
5	Ratification of remuneration of Cost Auditors.
6	Revision in the remuneration of Sri V.C. Nannapaneni (DIN: 00183315) Managing
	Director
7	Revision in the remuneration of Sri Rajeev Nannapaneni (DIN: 00183872) Director and Chief Executive Officer

• The following items of business were considered at the AGM:



- Chairman instructed the moderator for the VC to enable the Speaker shareholders to raise the comments/queries with regard to the reports and accounts. Director & CEO, Director & Executive Vice President (CES), Director & Executive Vice President (Tech. Operations) and CFO appropriately answered the queries raised by the members.
- The Chairman then informed that the combined results on the remote e-voting and e-voting during the AGM would be announced within forty-eight hours of conclusion of the AGM.
- The Company Secretary of the meeting thanked the Members for their active participation in the AGM and declared that the business for which the AGM is convened is completed.

The meeting was concluded at 11.26 a.m.

Thanking you,

Yours Faithfully, For NATCO Pharma Limited

Ch. Venkat Ramesh Company Secretary & Compliance Officer